Qardio welcomes new board members and chairman as the company continues to launch disruptive technology
The brand is pivoting its mission in healthcare and is eager to see the continued growth it will make with these new additions.
SAN FRANCISCO, C.A. – Aug. 9, 2022: Qardio, a leader in connected care with predictive insight for a changing world, is proud to welcome new members to its board: new Chairman Gregory Rich, and board members Dr. David Steinhaus and Leopoldo Zambeletti.
Taking over as chairman is Gregory Rich, who has held various positions in the healthcare industry, including Alpha Therapeutic Corporation, and was most recently the President and CEO of Grifols Inc.
“Qardio is currently paving the way in regard to patient healthcare,” says Rich. “I am honored to continue my work as Chairman in order to further provide better patient care and improve patient outcomes.”
Joining the board of directors is Dr. David Steinhaus. Steinhaus’s vast experience and previous leadership roles include Vice President and General Manager of Heart Failure and Chief Medical Officer of Cardiac Rhythm Management with Medtronic, as well as being a practicing electrophysiologist, and management of medical practices.
“The progress Qardio has made in improving its presence in global healthcare has been impressive. I am pleased to be able to help oversee the company’s success,” says Dr. Steinhaus.
Also joining the board is Leopoldo Zambeletti, who has held various healthcare industry positions, most notably as the former head of JP Morgan Healthcare Investing (EMEA). He currently resides on multiple boards of brands in healthcare, including Zambeletti Ltd., Faron, Touchlight, and more.
Currently, Qardio is pivoting its mission to bring improved healthcare not only to consumers but to the healthcare industry as a whole. Most recently, the brand has further expanded its global footprint with recent product developments, such as QardioDirect, and QardioCore.
“I am honored to have such a world class team on the board of directors”, says Mike Alvarez, CEO. “Qardio continues to launch wearable technology utilizing cloud based Artificial Intelligence to help patients and providers stay healthy. Our recent launches of QardioDirect, an innovative remote vitals monitoring platform and QardioCore, the only FDA approved ambulatory ECG holter and extended holter with dry electrode technology, is just the beginning of an exciting growth period for Qardio.”